Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

European Journal of Haematology

Volumn 80, Issue 4, 2008, Pages 296-298

  Ferrajoli, Alessandra ^a   Wierda, William G ^a   Lapushin, Ruth ^a   O'Brien, Susan M ^a   Faderl, Stefan ^a   Browning, Mary L ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alemtuzumab; Alemtuzumab levels; CD52; Chronic lymphocytic leukemia

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; DIPHENHYDRAMINE; FLUDARABINE; PARACETAMOL; VALACICLOVIR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; LYMPHOCYTOSIS; MALE; PNEUMONIA; PRIORITY JOURNAL; RASH; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; SALVAGE THERAPY; VIDARABINE;

EID: 40449085707     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01023.x     Document Type: Article

References (10)

1. Keating MJ, O'Brien S, Kontoyiannis D, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002 43 : 1755 62.
2. Hale G, Xia MQ, Tighe HP, et al. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990 35 : 118 27.
3. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998 95 : 427 36.
4. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004 104 : 948 55.
5. Isaacs JD, Manna VK, Rapson N, et al. CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 1996 35 : 231 40.
6. Tang SC, Hewitt K, Reis MD, et al. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low-grade lymphoma. Leuk Lymphoma 1996 24 : 93 101.
7. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003 98 : 773.
8. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 99 : 3554 61.
9. Cheson B, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999 17 : 1244 53.
10. Rebello P, Hale G. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 2002 260 : 285 302.